Pemphigus Herpetiformis Follow-up
- Author: Lawrence S Chan, MD; Chief Editor: Dirk M Elston, MD more...
Further Inpatient Care
The disease activities of pemphigus herpetiformis rarely require hospitalization. In a few patients, short-term hospitalization (< 10 d) may be helpful.
Further Outpatient Care
The disease activities of pemphigus herpetiformis range from mild to moderate. During the active disease period, provide follow-up care for patients on a monthly outpatient basis. These visits ensure that (1) patients are responding clinically to prescribed medications and (2) patients experience no serious adverse effects that require a change of medications. Typically, follow-up visits are not needed for patients in clinical remission and not on treatment.
Deterrence/Prevention
For pemphigus herpetiformis patients who are treated with systemic corticosteroid for longer than 1 month, combined calcium and vitamin D supplements should be instituted to prevent osteoporosis. The dosage and frequency of these supplements are stated in the 1996 recommendations established by the American College of Rheumatology Task Force.[17]
Prognosis
The prognosis for pemphigus herpetiformis usually is excellent.
Amagai M, Tsunoda K, Suzuki H, Nishifuji K, Koyasu S, Nishikawa T. Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus. J Clin Invest. Mar 2000;105(5):625-31. [Medline].
Kubota Y, Yoshino Y, Mizoguchi M. A case of herpetiform pemphigus associated with lung cancer. J Dermatol. Aug 1994;21(8):609-11. [Medline].
Palleschi GM, Giomi B. Herpetiformis pemphigus and lung carcinoma: a case of paraneoplastic pemphigus. Acta Derm Venereol. 2002;82(4):304-5. [Medline].
Marzano AV, Tourlaki A, Cozzani E, Gianotti R, Caputo R. Pemphigus herpetiformis associated with prostate cancer. J Eur Acad Dermatol Venereol. May 2007;21(5):696-8. [Medline].
Brod C, Fierlbeck G, Metzler G, Sonnichsen K, Rocken M, Schaller M. [Desmoglein 1-negative, desmoglein 3-positive pemphigus herpetiformis with involvement of oral mucous membranes]. J Dtsch Dermatol Ges. Apr 2005;3(4):280-2. [Medline].
Ishii K, Amagai M, Komai A, et al. Desmoglein 1 and desmoglein 3 are the target autoantigens in herpetiform pemphigus. Arch Dermatol. Aug 1999;135(8):943-7. [Medline].
Kubo A, Amagai M, Hashimoto T, et al. Herpetiform pemphigus showing reactivity with pemphigus vulgaris antigen (desmoglein 3). Br J Dermatol. Jul 1997;137(1):109-13. [Medline].
Verdier-Sevrain S, Joly P, Thomine E, et al. Thiopronine-induced herpetiform pemphigus: report of a case studied by immunoelectron microscopy and immunoblot analysis. Br J Dermatol. Feb 1994;130(2):238-40. [Medline].
Sanchez-Palacios C, Chan LS. Development of pemphigus herpetiformis in a patient with psoriasis receiving UV-light treatment. J Cutan Pathol. Apr 2004;31(4):346-9. [Medline].
Morita E, Amagai M, Tanaka T, Horiuchi K, Yamamoto S. A case of herpetiform pemphigus coexisting with psoriasis vulgaris. Br J Dermatol. Oct 1999;141(4):754-5. [Medline].
Chan LS, Vanderlugt CJ, Hashimoto T, et al. Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol. Feb 1998;110(2):103-9. [Medline].
Miura T, Kawakami Y, Oyama N, et al. A case of pemphigus herpetiformis with absence of antibodies to desmogleins 1 and 3. J Eur Acad Dermatol Venereol. Jan 2010;24(1):101-3. [Medline].
Lebeau S, Muller R, Masouye I, Hertl M, Borradori L. Pemphigus herpetiformis: analysis of the autoantibody profile during the disease course with changes in the clinical phenotype. Clin Exp Dermatol. Oct 23 2009;[Medline].
Montgomery JR, Chan LS. An unusual clinical presentation of pemphigus herpetiformis with marked response to dapsone. J Am Acad Dermatol. 2010;In press.
Hashimoto T, Ogawa MM, Konohana A, Nishikawa T. Detection of pemphigus vulgaris and pemphigus foliaceus antigens by immunoblot analysis using different antigen sources. J Invest Dermatol. Mar 1990;94(3):327-31. [Medline].
Ishii K, Amagai M, Hall RP, et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol. Aug 15 1997;159(4):2010-7. [Medline].
American College of Rheumatology. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines. Arthritis Rheum. Nov 1996;39(11):1791-801. [Medline].
Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. Oct 26 2006;355(17):1772-9. [Medline].
Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell. Nov 29 1991;67(5):869-77. [Medline].
Barranco VP. Mixed bullous disease. Arch Dermatol. Aug 1974;110(2):221-4. [Medline].
DeMento FJ, Grover RW. Acantholytic herpetiform dermatitis. Arch Dermatol. Jun 1973;107(6):883-7. [Medline].
Dias M, dos Santos AP, Sousa J, Maya M. Herpetiform pemphigus. J Eur Acad Dermatol Venereol. Jan 1999;12(1):82-5. [Medline].
Huhn KM, Tron VA, Nguyen N, Trotter MJ. Neutrophilic spongiosis in pemphigus herpetiformis. J Cutan Pathol. Jun 1996;23(3):264-9. [Medline].
Jablonska S, Chorzelski TP, Beutner EH, Chorzelska J. Herpetiform pemphigus, a variable pattern of pemphigus. Int J Dermatol. Jun 1975;14(5):353-9. [Medline].
Kuhl KA, Shofer FS, Goldschmidt MH. Comparative histopathology of pemphigus foliaceus and superficial folliculitis in the dog. Vet Pathol. Jan 1994;31(1):19-27. [Medline].
Maciejowska E, Jablonska S, Chorzelski T. Is pemphigus herpetiformis an entity?. Int J Dermatol. Nov 1987;26(9):571-7. [Medline].
Mahoney MG, Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest. Feb 1999;103(4):461-8. [Medline].
Micali G, Musumeci ML, Nasca MR. Epidemiologic analysis and clinical course of 84 consecutive cases of pemphigus in eastern Sicily. Int J Dermatol. Mar 1998;37(3):197-200. [Medline].
Nickoloff BJ, Karabin GD, Barker JN, et al. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol. Jan 1991;138(1):129-40. [Medline].
O'Toole EA, Mak LL, Guitart J, et al. Induction of keratinocyte IL-8 expression and secretion by IgG autoantibodies as a novel mechanism of epidermal neutrophil recruitment in a pemphigus variant. Clin Exp Immunol. Jan 2000;119(1):217-24. [Medline].
Robinson ND, Hashimoto T, Amagai M, Chan LS. The new pemphigus variants. J Am Acad Dermatol. May 1999;40(5 Pt 1):649-71; quiz 672-3. [Medline].
Santi CG, Maruta CW, Aoki V, Sotto MN, Rivitti EA, Diaz LA. Pemphigus herpetiformis is a rare clinical expression of nonendemic pemphigus foliaceus, fogo selvagem, and pemphigus vulgaris. Cooperative Group on Fogo Selvagem Research. J Am Acad Dermatol. Jan 1996;34(1):40-6. [Medline].
Schroder JM. Cytokine networks in the skin. J Invest Dermatol. Jul 1995;105(1 Suppl):20S-24S. [Medline].
Seitz CS, Staegemeir E, Amagai M, Rose C, Brocker EB, Zillikens D. Pemphigus herpetiformis with an autoimmune response to recombinant desmoglein 1. Br J Dermatol. Aug 1999;141(2):354-5. [Medline].
Shimizu K, Hashimoto T, Wang N, et al. A case of herpetiform pemphigus associated with autoimmune hemolytic anemia: detection of autoantibodies against multiple epidermal antigens. Dermatology. 1996;192(2):179-82. [Medline].

